Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

Shanghai Kaibao Pharmaceutical Co,Ltd. / Equity Bottom-Up

<ul>
  <li>Shanghai Kaibao is a specialized pharmaceutical company focused on Traditional Chinese Medicine (TCM), with its patented, exclusive product, Tanreqing Injection, serving as the primary revenue and profit driver. This product is a leading treatment for respiratory illnesses like bronchitis and pneumonia in China.</li>
  <li>The company has demonstrated a remarkable financial turnaround, evidenced by a 3-year net income CAGR of 38.91%. This growth follows a period of stagnation, signaling a potential resurgence, supported by high and stable gross margins consistently above 76%.</li>
  <li>Significant risks loom from high product concentration on Tanreqing and the stringent Chinese regulatory environment. Potential government-mandated price reductions through the National Reimbursement Drug List (NRDL) negotiations and competition from substitute treatments pose material threats to future profitability.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Shanghai Kaibao is a specialized pharmaceutical company focused on Traditional Chinese Medicine (TCM), with its patented, exclusive product, Tanreqing Injection, serving as the primary revenue and profit driver. This product is a leading treatment for respiratory illnesses like bronchitis and pneumonia in China.
  The company has demonstrated a remarkable financial turnaround, evidenced by a 3-year net income CAGR of 38.91%. This growth follows a period of stagnation, signaling a potential resurgence, supported by high and stable gross margins consistently above 76%.
  Significant risks loom from high product concentration on Tanreqing and the stringent Chinese regulatory environment. Potential government-mandated price reductions through the National Reimbursement Drug List (NRDL) negotiations and competition from substitute treatments pose material threats to future profitability.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Shanghai Kaibao Pharmaceutical Co,Ltd. (300039 CH) - Dec 2025

China

Shanghai Kaibao Pharmaceutical CO.,LTD. produces pharmaceutical products.  The Company's products include injection fluid, medical tablet, capsules, and Chinese medicine extracts.

Shanghai Kaibao Pharmaceutical Co,Ltd. (300039 CH)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Primer: Shanghai Kaibao Pharmaceutical Co,Ltd. (300039 CH) - Dec 2025

Shanghai Kaibao is a specialized pharmaceutical company focused on Traditional Chinese Medicine (TCM), with its patented, exclusive product,...

αSK